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Albuminuria and creatinine: simple, inexpensive and 
essential tests in the course of chronic kidney disease 
Chronic kidney disease (CKD), contrary to what was thought not long ago, is a com-
mon disease, and is currently considered a public health problem.1 This knowledge was 
possible due to the new definition that facilitated the diagnosis of CKD, mainly in its 
early stages, when it is frequently asymptomatic. Furthermore, early diagnosis and tre-
atment of CKD allow to implement interventions that reduce cardiovascular morbidity, 
the main cause of death in CKD patients worldwide. In fact, the relationship between 
CKD and CVD is really well known, one favoring the development and complicating 
the progression of the other.2 In both conditions, prevention through early diagnosis 
and the adoption of a healthy lifestyle constitute the first interventions to be taken.
It is worth emphasize that CKD is frequently silent in its early stages, so the patient 
may have no signs or symptoms that alert for its presence, what delays its diagnosis, 
postpones treatment, and favors unwanted outcomes. Particularly in its early stage, 
CKD can easily be identified through widely available and inexpensive laboratory tests, 
what allows to slow the progression to renal replacement therapy (RRT), identification 
and treatment of the most common complications, and prevention of early death.3  
The measurements of serum creatinine, frequently used to estimate glomerular fil-
tration rate (eGFR), and “micro” or “macro” albuminuria (the latter also denomi-
nated proteinuria) are tests of paramount importance for the diagnosis of CKD. In fact, 
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) consensus meet-
ing held in 2009, in London, UK4 endorsed the conceptional definition of CKD previ-
ously proposed by the NKF-KDOQI5 which defined CKD as any impairment of kidney 
function as evidenced by decreased GFR or other evidence of kidney damage, the latter 
including proteinuria, hematuria, abnormal kidney biopsy, or abnormal kidney imaging 
study present for 3 or more months. This definition is the basis of the current staging4,5 
of CKD and was responsible for the increased attention to the disease in clinical prac-
tice, research and public health. 
Plasma or serum creatinine is considered a good marker of changes in GFR in a 
certain patient, however, it underperforms in measuring absolute GFR.6 The major 
problems with creatinine are the analytical interference of non-creatinine chromo-
genes, its inverse relation with GFR, and its dependency on muscle mass. Moreover, 
serum creatinine increases with the ingestion of cooked meat, regardless of changes 
of renal function, a reason why it should be measured after 12 hours of a meat-free 
diet. The calculation of eGFR by MDRD7 and CKD-EPI8 equations derived from se-
rum creatinine, age, gender, and race, which essentially correct for muscle mass, is 
now wildly recommended. If muscle mass markedly differs from the mean for age, 
race, and gender, eGFR will provide less reliable results, such as those calculated in 
amputee and undernourished patients.5 For such patients, the recommendation is to 
determine the creatinine clearance in a urine sample collected over 24 hours.5 The 
eGFR has been validated in individuals of different races, Brazilian included.9 The use 
of eGFR is also not recommended in children, pregnant women, elderly, and at both 
extremes of weight.5
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The eGFR by the MDRD equation is not sufficiently accurate for values over 60 mL/
min/1.73m2, and the current recommendation is that laboratories which already estimate 
renal function when measuring serum creatinine do not mention results above that value. 
In this setting, the CKD-EPI equation has been recommended.8 It is important to remem-
ber that eGFR reflects GFR only in the steady state, and is not recommended to estimate 
the renal function of patients with acute kidney failure, a clinical situation where creati-
nine clearance is more appropriate.5 The identification of reduced eGFR requires repeat 
the measurement after three months, aiming to confirm or not the chronicity of impair-
ment of kidney function, or presence or absence of CKD.5 
Screening for proteinuria can be done by detecting urinary total protein as well as its 
fraction, albumin. The dipstick test, widely used for screening of proteinuria, is practical, 
but its performance depends on urine flow. Creatinine is excreted in the urine at a rela-
tively constant rate and can be used for quantifying proteinuria (protein/creatinine ratio 
or PCR) or albuminuria (albumin/creatinine ratio or ACR) in spot urine sample. Besides 
its convenience, proteinuria determined in spot urine sample presents excellent correla-
tion with measurements in 24 hours urine samples.10  
The ACR plays a central role in diabetic kidney disease (DKD) and should be used, at 
least annually, for both screening kidney injury and follow-up of patients with established 
DKD. In non-diabetic patients, however, the role played by ACR or PCR is yet to be es-
tablished, because of the controversial recommendations of the guidelines.5,11,12 
Most studies about outcomes and interventions are based on the determination of 
total proteinuria, and, less frequently, on albuminuria, which is more expensive. The 
Coomassie brilliant blue R-250 staining to detect microalbuminuria13 has been recently 
reported as a method with excellent sensitivity and low cost (each test costs about five 
cents of Real), what would allow its use in detecting renal parenchymal injury in the early 
stages of CKD.
It is worth noting that the classification of CKD into stages, currently adopted world-
wide, is based on eGFR and presence of albuminuria (proteinuria).4,5,12 (Chart 1)
Chart 1 rElationship of albuminuria and glomErular filtration in chronic kidnEy disEasE  
 diagnosis and staging
Estimate glomerular filtration (mL/min/1.73m2) 
















CKD (-) CKD (-) CKD (+) CKD (+) CKD (+) CKD (+)
Microalbuminuria 
(30-300 mg/day)
CKD (+) CKD (+) CKD (+) CKD (+) CKD (+) CKD (+)
Gross albuminuria or proteinuria 
(> 300 mg/day)
CKD (+) CKD (+) CKD (+) CKD (+) CKD (+) CKD (+)
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But the determinations of eGFR and albuminuria, beside of being key in the diagnosis 
and staging of CKD, are also important in predicting outcomes. (Chart 2). The benefits 
of assessing kidney function based on eGFR are not limited to predicting which patients, 
over the course of the disease, will need RRT, but also include the identification of those 
at increased risk for accelerated loss of kidney function associated with morbidity and 
mortality. The lower the GFR, the more likely the need for dialysis or renal transplanta-
tion. Epidemiological studies have evidenced that the risk of a stage 1 or 2 CKD patient 
requiring renal replacement therapy (RRT) is lower than that of a stage 3 or 4 CKD 
patient, because the time required to exhaust the renal functional reserve of the former 
is longer. These observations, however, are not absolute, because the rate of progression 
of the kidney disease depends on several determinants, such as patient’s age, CKD etiol-
ogy, presence of risk factors associated with progression, and comorbidities, particularly 
those of cardiovascular origins. Naturally, the higher the amount of data about eGFR 
available and longer the study, more reliable the calculation of eGFR fall will be.10,14,15 
Unfortunately, so far, only a few studies have assessed the risk factors determining acceler-
ated kidney function loss. Such studies should ideally provide data of sequential follow-up 
for assessing changes in eGFR over time.
So far, it is not yet clear whether the best predictor of progressive CKD is the severity 
of the loss of filtration capacity (expressed as eGFR) or the presence of markers of renal 
parenchymal lesion (expressed by albuminuria). Usually, the incidence of CKD increases 
as baseline eGFR worsens.16 However, the CKD course can be different, depending on 
the presence of any evidence of renal parenchymal lesion. In fact, the incidence of CKD 
is approximately one hundred times greater in a patient with proteinuria than in another 
patient with the same eGFR, but with no proteinuria. In a population-based study car-
ried out in Japan, the authors reported that a stage 1 or 2 CKD patient with proteinuria 
detected by dipstick had a higher risk of requiring RRT than a stage 3, and even stage 4 
CKD patient with a negative test.17 More recent data originated from the Multiple Risk 
Factor Intervention Trial (MRFIT) have confirmed those observations. The risk of a stage 
3 CKD patient without proteinuria requiring RRT is only 2.4 times greater than that of 
the population with no CKD, but it is 33 times greater if the same patient has proteinuria. 
It is worth noting that the risk of progression to end stage renal failure (ESRF) is approxi-
mately 12 times increased for a stage 1 or 2 CKD patient with proteinuria, that is, greater 
than that observed in a stage 3 patient without proteinuria.18
Chart 2 rElEvancE of EstimatEd glomErular filtration ratE and of albuminuria in thE coursE  
 of chronic kidnEy disEasE (ckd)
1. CKD screening and diagnostic confirmation
2. CKD staging
3. Marker of unfavorable outcomes
4. Prevention of medical error (drug nephrotoxicity)
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In the Prevention of Renal and Vascular Endstage Disease (PREVEND) study, pro-
spectively conducted in the Dutch population, the participants were sequentially assessed 
every three to four years over 6.2 years.20 In a cohort of 6,879 participants, the eGFR was 
observed to decrease at a rate of 0.45 ± 1.60 mL/min/1.73m2 per year. When adjusted 
for age and sex, the eGFR decrease was gradually accentuated with the increase in pro-
teinuria.19 At any CKD stage, the rate of decline in eGFR was greater in patients with 
proteinuria than in patients without proteinuria. The study also identified high blood 
pressure, hyperglycemia, and albuminuria as independent risk factors for progression to 
ESRF in both sexes.20
By the end of the last century, it was evident that being a CKD patient on dialysis 
was a predisposing factor for increased likelihood of death due to CVD. For example, 
the likelihood of death of a 20-year-old patient on RRT is 500 times greater than that of 
a healthy individual of the same age, and is about the same of an 80-year-old patient.21 
However, the association of CKD with cardiovascular mortality is not limited to dialysis 
patients, and can be observed in patients at the pre-dialysis stages of the disease. It is ex-
tremely disturbing to know that the reduction of eGFR gradually associates with higher 
mortality (mainly due to CVD) and that a patient with stage 4 CKD has twice the chance 
of death than begin dialysis treatment.22 However, it is possible that other markers beside 
the decline of eGFR associate with higher mortality in CKD. For example, the adjusted 
mortality rate of a CKD patient in stage 1 or 2 (eGFR > 60 mL/min/1.73m2) and albumin-
uria is twice that of a CKD patient in stage 3A (eGFR of 45-59 mL/min/1.73m2) without 
albuminuria.23 
Currently, increased levels of albuminuria24 and decreased eGFR25 are accepted as risk 
factors for cardiovascular mortality independent from the so-called “traditional” risk fac-
tors. However, the reliability of those two markers for predicting cardiovascular events is 
not fully settled. For example, studies carried out in Holland26 and in the United States27 
have reported a significant increase in the occurrence of cardiovascular events in patients 
with CKD stage 3B (or eGFR < 45 mL/min/1.73m2) without proteinuria. On the other 
hand, in a study with patients after myocardial infarction28 and in two other population-
based studies,29,30 the risk of cardiovascular events adjusted for age and sex was not sta-
tistically elevated in patients with stage 3 CKD  and without proteinuria, although it was 
clearly increased in those who had proteinuria.
In our study of outpatients with heart failure (HF) stages B and C, CKD stages 3 to 5 
was diagnosed in 50% of the cases. After 12 months of follow up, death or hospitaliza-
tion due to cardiac decompensation occurred respectively in 100% and 65% of patients 
with HF stages B and C if the patient presented CKD at baseline.31 After adjusting for 
other prognostic factors for HF at baseline, it was observed that CKD independently in-
creased by 3.6 times the likelihood of unfavorable outcomes. 
Interestingly, the results of the studies mentioned above regarding the occurrence of in-
creased risk for CVD in patients with CKD stage 1 or 2 compared with individuals with-
out kidney disease are very similar to the observed relation between CKD with progres-
sion to RRT. The parallel between the impact of albuminuria as an independent predictor 
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of cardiovascular and renal diseases is impressive. Until recently, macroalbuminuria was 
considered to be only a mark of glomerular injury, while microalbuminuria indicated the 
occurrence of vascular injury and was not always related to renal impairment. Thus mac-
roalbuminuria was considered a predictor of CKD, while microalbuminuria was used as 
a risk factor for CV events. Nowadays, however, it is evident that macroalbuminuria also 
associates with cardiovascular outcomes,32,33 and microalbuminuria identifies patients 
with CKD and predicts those who will progress to RRT in diabetes34,35 or hipertensives,36 
or in the general population.19,20,29 
In conclusion, estimated GFR from plasma creatinine and measurement of microalbu-
minuria or macroalbuminuria (proteinuria) are simple, widely available, and high relevant 
clinical tests. They should be regularly performed in patients at the risk of CKD (diabetics, 
hypertensives, elderly, relatives on RRT), particularly in the pre-clinical stages of the disease 
(when eGFR is greater than 60 mL/min/1.73m2), as well as in patients with CVD. They 
are interactive tests and when used together, constitute a powerful propedeutic tool in the 
diagnosis and prognosis of CKD, and predictors of adverse outcome including mortality.
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